Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""van Herpen CML"" wg kryterium: Autor


Tytuł :
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)
Autorzy :
van Herpen CML (AUTHOR)
Locati LD (AUTHOR)
Buter J (AUTHOR)
Thomas J (AUTHOR)
Bogaerts J (AUTHOR)
Lacombe D (AUTHOR)
de Mulder P (AUTHOR)
Awada A (AUTHOR)
Licitra L (AUTHOR)
Bernier J (AUTHOR)
Vermorken JB (AUTHOR)
Pokaż więcej
Źródło :
European Journal of Cancer. Nov2008, Vol. 44 Issue 17, p2542-2545. 4p.
Czasopismo naukowe
Tytuł :
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
Autorzy :
van Cruijsen H (AUTHOR)
Voest EE (AUTHOR)
Punt CJA (AUTHOR)
Hoekman K (AUTHOR)
Witteveen PO (AUTHOR)
Meijerink MR (AUTHOR)
Puchalski TA (AUTHOR)
Robertson J (AUTHOR)
Saunders O (AUTHOR)
Jürgensmeier JM (AUTHOR)
van Herpen CML (AUTHOR)
Giaccone G (AUTHOR)
Pokaż więcej
Źródło :
European Journal of Cancer. Mar2010, Vol. 46 Issue 5, p901-911. 11p.
Czasopismo naukowe
Tytuł :
Informal caregiver well-being during and after patients' treatment with adjuvant chemotherapy for colon cancer: a prospective, exploratory study.
Autorzy :
Langenberg SMCH; Department of Medical Oncology, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Poort H; Dana-Farber Cancer Institute, Department of Psychosocial Oncology and Palliative Care, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Wymenga ANM; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands.
de Groot JW; Department of Internal Medicine, Isala, Zwolle, The Netherlands.
Muller EW; Department of Internal Medicine, Slingeland Ziekenhuis, Doetinchem, The Netherlands.
van der Graaf WTA; Department of Medical Oncology, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Prins JB; Department of Medical Psychology, Radboud University Medical Center, Nijmegen, The Netherlands.
van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. .
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2021 May; Vol. 29 (5), pp. 2481-2491. Date of Electronic Publication: 2020 Sep 15.
Typ publikacji :
Journal Article
MeSH Terms :
Social Support*
Caregivers/*psychology
Chemotherapy, Adjuvant/*methods
Colonic Neoplasms/*drug therapy
Quality of Life/*psychology
Female ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Prospective Studies
Czasopismo naukowe
Tytuł :
Baseline effector cells predict response and NKT cells predict pulmonary toxicity in advanced breast cancer patients treated with everolimus and exemestane.
Autorzy :
Willemsen AECAB; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Medical Oncology, 6525 GA Nijmegen, the Netherlands. Electronic address: .
He X; Radboud University Medical Center, Department of Laboratory Medicine, 6525 GA Nijmegen, the Netherlands.
van Cranenbroek B; Radboud University Medical Center, Department of Laboratory Medicine, 6525 GA Nijmegen, the Netherlands.
de Jong PC; St. Antonius Ziekenhuis, Department of Medical Oncology, 3435CM Nieuwegein, the Netherlands.
de Boer M; Maastricht University Medical Center, Division of Medical Oncology Department of Internal Medicine, GROW-School of Oncology and Developmental Biology, 6229 HX Maastricht, the Netherlands.
Joosten I; Radboud University Medical Center, Department of Laboratory Medicine, 6525 GA Nijmegen, the Netherlands.
Koenen HJPM; Radboud University Medical Center, Department of Laboratory Medicine, 6525 GA Nijmegen, the Netherlands.
van Herpen CML; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Medical Oncology, 6525 GA Nijmegen, the Netherlands.
Gerritsen WR; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Medical Oncology, 6525 GA Nijmegen, the Netherlands.
Pokaż więcej
Źródło :
International immunopharmacology [Int Immunopharmacol] 2021 Apr; Vol. 93, pp. 107404. Date of Electronic Publication: 2021 Jan 30.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Merkel Cell Carcinoma: New Trends.
Autorzy :
Zwijnenburg EM; Department of Radiation Oncology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Lubeek SFK; Department of Dermatology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Werner JEM; Department of Surgery, Radboudumc, 6525GA Nijmegen, The Netherlands.
Amir AL; Department of Pathology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Weijs WLJ; Department of Maxillofacial Surgery, Radboudumc 6525GA Nijmegen, The Netherlands.
Takes RP; Department of Head and Neck Surgery, Radboudumc, 6525GA Nijmegen, The Netherlands.
Pegge SAH; Department of Radiology and Nuclear Medicine, Radboudumc, 6525GA Nijmegen, The Netherlands.
van Herpen CML; Department of Medical Oncology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Adema GJ; Department of Radiation Oncology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Kaanders JHAM; Department of Radiation Oncology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Pokaż więcej
Źródło :
Cancers [Cancers (Basel)] 2021 Mar 31; Vol. 13 (7). Date of Electronic Publication: 2021 Mar 31.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure.
Autorzy :
Krens SD; Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Lubberman FJE; Department of Pharmacy, Ziekenhuis Gelderse Vallei, Ede, The Netherlands.
van Egmond M; Department of Clinical Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
Jansman FGA; Department of Pharmacy, Deventer Hospital, Deventer, The Netherlands.; PharmacoTherapy, -Epidemiology & -Economics, University of Groningen, Groningen Research Institute of Pharmacy, Groningen, The Netherlands.
Burger DM; Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Hamberg P; Department of Medical Oncology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
Vervenne WL; Department of Medical Oncology, Deventer Hospital, Deventer, The Netherlands.
Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
van der Graaf WTA; Department of Medical Oncology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Desar IME; Department of Medical Oncology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
van Erp NP; Department of Clinical Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2021 Jun 01; Vol. 148 (11), pp. 2799-2806. Date of Electronic Publication: 2021 Jan 19.
Typ publikacji :
Journal Article
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies